How Reglan Use Can Lead to Tardive Dyskinesia: Recognizing Symptoms and Getting a Diagnosis

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Specific Legal Concerns

If you or a loved one has been taking Reglan and noticed unusual involuntary movements, you may be experiencing tardive dyskinesia. This condition is a known risk of prolonged use of metoclopramide, the active ingredient in Reglan. Decades of clinical research have established a clear link between cumulative exposure and movement disorders, making awareness essential for early detection. This page explains the symptoms, diagnosis, and monitoring considerations for Reglan-related tardive dyskinesia.

Understanding Reglan and Its Approved Uses

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux that has not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The approved duration for gastroesophageal reflux is 4 to 12 weeks, and for diabetic gastroparesis, treatment should not exceed 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is not recommended for pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Tardive Dyskinesia: A Serious Neurological Condition

Tardive dyskinesia is a syndrome of potentially irreversible and disfiguring involuntary movements, typically involving the face or tongue, and sometimes the trunk or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition is caused by metoclopramide, the active ingredient in Reglan, and the risk of developing TD increases with longer treatment duration and higher total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA has issued a boxed warning for Reglan, stating that metoclopramide can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning also notes that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be discontinued immediately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism of Action and Clinical Presentation

The mechanistic pathway linking Reglan to TD involves metoclopramide's action as a dopamine receptor antagonist in the central nervous system. Chronic blockade of dopamine D2 receptors in the basal ganglia is believed to lead to receptor upregulation and supersensitivity, which can manifest as the involuntary movements characteristic of TD. The drug may also suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect can make it difficult for patients and clinicians to recognize the onset of TD until movements become more pronounced. Clinical presentation of TD typically includes repetitive, involuntary movements such as lip smacking, tongue protrusion, grimacing, and rapid blinking. In more advanced cases, movements may involve the trunk and extremities, including choreiform or athetoid motions. Diagnosis is based on clinical examination and history of exposure to a dopamine receptor blocking agent like metoclopramide. There is no definitive diagnostic test, and the condition can be irreversible even after discontinuation of the offending drug.

Statute of Limitations for Reglan Claims in California

For patients in California who have developed TD after using Reglan, several legal considerations arise. The statute of limitations for personal injury claims in California is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For claims involving prescription drugs, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Reglan caused their TD. Given that TD can develop insidiously and may be masked by the drug itself, the timeline between exposure and documented harm can be prolonged. Patients may have taken Reglan for months or years before noticing symptoms, and diagnosis may be further delayed. This latency period can complicate the determination of when the statute of limitations begins. Adequacy of warnings is a central issue in potential litigation. The FDA boxed warning clearly states the risk of TD and the need for short-term use, but questions may arise about whether prescribers and patients received sufficient information about the specific risk of irreversible movement disorders, especially when Reglan is used off-label or for longer than recommended durations. The label explicitly warns that the risk increases with duration and cumulative dose, and that Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, if a patient was not adequately informed of these risks, or if the drug was prescribed for an extended period without proper monitoring, there may be grounds for a claim based on failure to warn.

Legal Considerations for Affected Patients

Attorney-related considerations for affected patients include the need to gather medical records documenting Reglan use, the onset and progression of TD symptoms, and any communication with healthcare providers about the risks. Expert testimony may be required to establish the causal link between Reglan and TD, and to address the adequacy of warnings. Patients should also be aware that California law requires claims to be filed within the applicable statute of limitations, and that delays in diagnosis can affect the calculation of this deadline. In summary, Reglan carries a known risk of causing tardive dyskinesia, a potentially irreversible movement disorder, with risk increasing with longer use and higher doses. The drug's labeling includes a boxed warning and specific contraindications, but patients who develop TD after prolonged or inadequately monitored use may have legal recourse. In California, the statute of limitations for such claims is generally two years from discovery of the injury, but the timeline can be complex due to the delayed onset and diagnosis of TD. Affected individuals should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in California?

In California, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. The discovery rule may apply, meaning the clock starts when the patient knew or should have known that Reglan caused their TD. Due to the delayed onset and diagnosis of TD, the timeline can be complex, so consulting an attorney is recommended.

What is tardive dyskinesia and how is it caused by Reglan?

Tardive dyskinesia (TD) is a syndrome of potentially irreversible involuntary movements, typically involving the face or tongue, and sometimes the trunk or extremities. It is caused by metoclopramide, the active ingredient in Reglan, which blocks dopamine receptors in the brain. The risk increases with longer treatment duration and higher cumulative doses. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.